{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:55:01Z","timestamp":1788893701096,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejca.2020.12.015","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T01:36:45Z","timestamp":1610933805000},"page":"143-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Exceptional response to anti-PD-1 treatment in a patient with metastatic cutaneous hidradenocarcinoma"],"prefix":"10.1016","volume":"145","author":[{"given":"H.","family":"Obermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Schmidle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Steimle-Grauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-5375","authenticated-orcid":false,"given":"N.","family":"Pfarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0296-3567","authenticated-orcid":false,"given":"C.","family":"Posch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.12.015_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/his.12767","article-title":"Malignant sweat gland tumours: an update","volume":"67","author":"Cardoso","year":"2015","journal-title":"Histopathology"},{"key":"10.1016\/j.ejca.2020.12.015_bib2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/DAD.0b013e3181984f10","article-title":"Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2\/neu gene expression\/amplification, TP53 gene mutation analysis, and t(11;19) translocation","volume":"31","author":"Kazakov","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.ejca.2020.12.015_bib3","first-page":"3","article-title":"p53 expression in sweat gland tumors","volume":"47","author":"Biernat","year":"1996","journal-title":"Pol J Pathol Off J Polish Soc Patholg"},{"key":"10.1016\/j.ejca.2020.12.015_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s43018-020-0027-5","article-title":"A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies","volume":"1","author":"Degasperi","year":"2020","journal-title":"Nature Canc"},{"key":"10.1016\/j.ejca.2020.12.015_bib5","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.4081\/rt.2015.6082","article-title":"Management of metastatic apocrine hidradenocarcinoma with chemotherapy and radiation","volume":"7","author":"Miller","year":"2015","journal-title":"Rare Tumors"},{"key":"10.1016\/j.ejca.2020.12.015_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1468-3083.2009.03301.x","article-title":"Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma","volume":"24","author":"Battistella","year":"2010","journal-title":"J Eur Acad Dermatol Venereol : JEADV"},{"key":"10.1016\/j.ejca.2020.12.015_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.12.015_bib8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1634\/theoncologist.2020-0014","article-title":"Efficacy and safety of immune checkpoint inhibitors in patients with microsatellite instability-high end-stage cancers and poor performance status related to high disease burden","volume":"25","author":"Pietrantonio","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2020.12.015_bib9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:30:48Z","timestamp":1760733048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920314404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":9,"alternative-id":["S0959804920314404"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.12.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exceptional response to anti-PD-1 treatment in a patient with metastatic cutaneous hidradenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}